logo-loader

Apricus Biosciences raises US$4.6mln through share issue

Published: 01:10 24 Sep 2016 AEST

picture of dollars
Money will fund roll-out of Vitaros across Europe

Apricus Biosciences, Inc (NASDAQ:APRI) has raised US$4.6mln through a placing with institutional shareholders at US$0.35.

The issue comes with a warrant  exercisable at US$0.45 per share with the money earmarked for general working capital.

San Diego-based, Apricus’s key product is erectile disfunction cream Vitaros, which is being steadily rolled out in Europe.

Earlier this month, Slovakia and the Czech Republic became the two latest European countries where the product went on sale.

The group intends to re-file its application for the US later this year after the Food and Drug Administration raised safety and manufacturing in the original Vitaros submission.

Shares eased 14% to 0.342.

 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

11 hours, 37 minutes ago